Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
2
67%
Ph not_applicable
1
33%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Completed(1)

Detailed Status

Not yet recruiting2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 22 (66.7%)
N/A1 (33.3%)

Trials by Status

not_yet_recruiting267%
completed133%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruitingphase_2

125I Seed Implantation Plus Systemic Therapy for Oligoprogressive NSCLC or Colorectal Cancer

NCT07333651
not_yet_recruitingphase_2

125I Seed Brachytherapy Combined With Immunotherapy for Primary, Recurrent, or Metastatic Malignant Tumors

NCT07277777
completednot_applicable

PD-1 Inhibitor Combined With 125I Seed Implantation for Hepatocellular Carcinoma's Extrahepatic Metastasis: Efficacy and Safety

NCT06991907

Clinical Trials (3)

Showing 3 of 3 trials
NCT07333651Phase 2

125I Seed Implantation Plus Systemic Therapy for Oligoprogressive NSCLC or Colorectal Cancer

Not Yet Recruiting
NCT07277777Phase 2

125I Seed Brachytherapy Combined With Immunotherapy for Primary, Recurrent, or Metastatic Malignant Tumors

Not Yet Recruiting
NCT06991907Not Applicable

PD-1 Inhibitor Combined With 125I Seed Implantation for Hepatocellular Carcinoma's Extrahepatic Metastasis: Efficacy and Safety

Completed

All 3 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
3